KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Other Non-Current Liabilities: 2009-2025

Historic Other Non-Current Liabilities for Teva Pharmaceutical Industries (TEVA) over the last 12 years, with Sep 2025 value amounting to $3.7 billion.

  • Teva Pharmaceutical Industries' Other Non-Current Liabilities fell 15.65% to $3.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year decrease of 15.65%. This contributed to the annual value of $4.0 billion for FY2024, which is 0.22% up from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Other Non-Current Liabilities of $3.7 billion as of Q3 2025, which was down 6.96% from $3.9 billion recorded in Q2 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Other Non-Current Liabilities registered a high of $4.4 billion during Q2 2024, and its lowest value of $2.2 billion during Q3 2021.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $4.0 billion (2025), whereas its average is $4.0 billion.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Other Non-Current Liabilities soared by 75.17% in 2022, and later fell by 15.65% in 2025.
  • Quarterly analysis of 5 years shows Teva Pharmaceutical Industries' Other Non-Current Liabilities stood at $2.6 billion in 2021, then soared by 53.03% to $3.9 billion in 2022, then increased by 1.88% to $4.0 billion in 2023, then climbed by 0.22% to $4.0 billion in 2024, then decreased by 15.65% to $3.7 billion in 2025.
  • Its last three reported values are $3.7 billion in Q3 2025, $3.9 billion for Q2 2025, and $4.0 billion during Q1 2025.